Introduction
Data from preclinical studies and clinical trials indicate that high titers of anti-amyloid-␤ (A ␤ ) antibodies may prevent the accumulation of toxic forms of A ␤ peptide and can be beneficial to Alzheimer's disease (AD) patients [1] [2] [3] [4] [5] . However, in one clinical trial, immunization with an adjuvant A ␤ peptide vaccine resulted in meningoencephalitis in 6% of subjects, likely due to the generation of autoreactive T cells [5] [6] [7] . Previously, we suggested that an epitope vaccine composed of a self-B cell epitope of A ␤ peptide and a foreign T helper cell epitope would be safe in humans since it should reduce the risk of an adverse T-cell-mediated autoimmune response while inducing a strong antibody response to A ␤ . Using this strategy, we have developed different epitope vaccines based on peptide, recombinant protein or DNA [8] [9] [10] . Our DNA-based epitope vaccine (DepVac), composed of three copies of a short A ␤ B cell epitope fused with the foreign universal Th cell epitope, PADRE, and macrophage-derived chemokine, was immunogenic and safe in mice [8] . However, although DNA vaccines have been used to induce immune responses in small animal models for more than a decade, low immunogenicity in large animals and humans has limited their utility.
Accordingly, successful translation of a DNA vaccine to the clinical setting requires a suitable method for effective intracellular delivery. Electroporation (EP)-and gene gun (GG)-mediated administration are the most effective physical methods for delivering DNA plasmids in vivo and both are currently being tested in clinical trials [11, 12] . GG is a needle-free ballistic device which delivers gold beads coated with plasmid DNA into the epidermal layer of skin and drives strong immune response to DNA vaccines in animals [8] and humans [12] . EP is a technique for intracellular delivery based on the brief application of electrical fields in the target region of tissue. EP delivery of DNA vaccines enhances immune responses by several orders of magnitude compared to conventional injection in animal models [13] and humans [11] . A previous study demonstrated superior T cell responses and tumor control with EP delivery compared to GG [14] . The goal of the current study was to evaluate the efficacy of antibody responses to DepVac delivered intramuscularly by EP or intradermally by GG. The results indicate that DepVac delivered by both methods induced potent titers of anti-A ␤ antibodies, as well as strong cellular responses against the foreign Th epitope, PADRE, but not self-A ␤ 40 .
Animals and Methods
Mice, DNA Immunizations, Detection of Humoral and Cellular Immune Responses and Functional Activity of Antibodies C57BL/6 mice (5-6 weeks old; Jackson Laboratory, Calif., USA) were immunized on days 0, 14 and 28 with 10 g/mouse DepVac [8] or noncoding control vector in a single anterior tibial muscle using the TDS-IM EP system (Ichor Medical Systems, Calif., USA) as described in Luxembourg et al. [15] or by intradermal delivery with three shots into the skin of the abdomen with GG bombardment (Bio-Rad, Calif., USA) [8, 10] . Concentrations of anti-A ␤ antibodies and their isotype profiles were measured in sera collected 12 days after each administration as described previously [8, 10] . To detect binding of immune sera to different forms of A ␤ 42 peptide, a dot blot assay was run as described in Petrushina et al. [9] . To detect binding of immune sera to native amyloid (plaques), immunohistochemistry was performed on brain sections from a control or AD patient obtained from the University of California, Irvine, Calif., USA [8] [9] [10] . T cell proliferation was analyzed in splenocyte cultures restimulated in vitro with 10 g/ml of PADRE peptide, A ␤ 40 peptide, or with an irrelevant peptide using a [ 3 H]-thymidine incorporation assay; stimulation index was calculated as described earlier [10] . ELISPOT assay was used to determine the number of antigen-specific cells producing cytokines (IFN-␥ and IL-4) as described in Petrushina et al. [9] .
Statistical Analysis Prism 3.03 software (GraphPad Software, Calif., USA) was applied in the statistical analysis of the data. Statistically significant differences were examined using a t test and p ! 0.05 was considered significant. fig. 1 a) . The results demonstrated that both methods are effective in inducing strong humoral immune responses. The level of anti-A ␤ antibodies after EP versus GG delivery was equivalent; after the third immunization, concentrations of antibodies were 145.1 8 69.2 and 167.9 8 57.3 g/ml, respectively. Of note, intradermal and intramuscular immunizations of mice with DepVac without using any delivery device generated low titers of anti-A ␤ antibodies: 0.84 8 1.4 and 21.3 8 17.5 g/ml, respectively. No anti-A ␤ response was seen in mice immunized with noncoding vector. Interestingly, EP-mediated vaccination induced predominantly IgG2a b isotypes of antibodies (IgG1/IgG2a b ratio was 0.61), whereas the antibodies produced after GG vaccination were mostly of the IgG1 isotype (IgG1/IgG2a b ratio was 11.87) ( fig. 1 b) . These data were in accordance with other reports [8, 9, 16, 17] , which indicates that these techniques may differ in activation of Th1 and Th2 pathways. One possible explanation could be connected with differential delivery of DNA. In case of muscle immunization, CpG motifs on plasmid backbone may interact with receptors in APC located in a target tissue and induce proinflammatory cytokines and Th1 type of immune response [18] , while GG inoculation delivers DNA directly into the nucleus bypassing CpG receptors. Other explanations for these differences are also possible.
Results and Discussion

DepVac Induces Strong and Therapeutically Potent Anti-A ␤ Antibodies in Mice Immunized with TDS-IM and GG
To demonstrate the functional activity of the anti-A ␤ antibodies, we analyzed binding of antisera to A ␤ plaques in brain tissues from an AD case. The immune sera from the EP and GG delivery groups bound to ␤ -amyloid plaques and this binding was specific since it was blocked by preabsorption of antisera with A ␤ 42 peptide (data not shown) and was not observed with control sera ( fig. 1 c) . Currently, it is thought that oligomers are the most toxic forms of A ␤ responsible for disrupting neuronal functions and inducing cognitive decline in AD [1] . Therefore, we analyzed binding of immune and control sera to various forms of amyloid and demonstrated that only immune sera bound to monomeric, oligomeric and fibrillar A ␤ 42 peptide ( fig. 1 d) .
EP-and GG-Mediated Immunizations with DepVac Induce Strong Cellular Immune Responses
To determine if enhancement of antibody responses after DepVac immunization by TDS-IM and GG is tied to higher T helper cell activation, we analyzed T cell responses in vaccinated mice. ELISPOT assay demonstrated that EP and GG delivery methods induced activation of similar numbers of IFN-␥ and IL-4 producing cells after restimulation of immune splenocytes with PADRE peptide, which were significantly higher compared with control groups (p ^ 0.001 and p ^ 0.01, respectively) ( fig. 2 a) . We also evaluated antigen-specific T cell activation by measuring T cell proliferation in splenocyte cultures restimulated with PADRE or irrelevant peptide. Data generated in this proliferation assay ( fig. 2 b) were in accordance with ELISPOT data presented in figure 2 a. Of note, as we expected from our previous studies [8, 9] , anti-A ␤ T cell responses were not detected in immune splenocyte cultures (data not shown).
In conclusion, this study demonstrated that EP and GG delivery of DepVac were equally effective in generating anti-A ␤ humoral and anti-PADRE cellular immune responses, although the antibody isotype responses were significantly different. With GG delivery, a much smaller dose range can be evaluated than with intramuscular EP since only a limited amount of DNA can be loaded on the gold beads; thus, multisite administrations may be required in humans to achieve target responses. Therefore, based on the data presented here plus the larger potential dosing range provided by intramuscular EP delivery, we initiated preclinical testing of DepVac in rabbits and nonhuman primates using EP. If safe and effective in these species, the vaccine will be evaluated in a human clinical trial. 
